Related Experiment Video

Updated: Sep 20, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

[Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia]

Krisztina Kádár1

  • 1Gottsegen György Országos Kardiológiai Intézet, Gyermekszív Központ.

Orvosi Hetilap
|August 7, 2003
PubMed

Insights

Idebenone treatment significantly improved cardiac function in a child with Friedreich ataxia and hypertrophic cardiomyopathy. This suggests idebenone is effective for managing this severe heart condition associated with the disease.

Area of Science:

  • Cardiology
  • Neurology
  • Genetics

Background:

  • Friedreich ataxia is a rare genetic disorder.
  • It can lead to severe hypertrophic cardiomyopathy.
  • Mitochondrial dysfunction and iron dysregulation are implicated in the cardiac pathology.

Observation:

  • A 15-year-old patient with Friedreich ataxia presented with severe hypertrophic cardiomyopathy.
  • Treatment with idebenone was initiated based on preliminary literature findings.

Findings:

  • After 3 months of idebenone treatment, significant improvements were observed.
  • Echocardiographic parameters showed reduced muscle thickness and improved diastolic function.
  • Electrocardiogram (ECG) revealed a decrease in ischemic signs.

Implications:

  • These findings support preliminary data on idebenone's efficacy.
  • Idebenone may be a valuable therapeutic option for Friedreich ataxia patients with hypertrophic cardiomyopathy.
  • Widespread use could improve the prognosis of this life-threatening cardiomyopathy.
Abstract

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...